SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Amgen Inc. – ‘8-K’ for 3/4/21 – ‘XML’

On:  Thursday, 3/4/21, at 8:39am ET   ·   For:  3/4/21   ·   Accession #:  1193125-21-68571   ·   File #:  1-37702

Previous ‘8-K’:  ‘8-K’ on / for 2/2/21   ·   Next:  ‘8-K’ on / for 4/16/21   ·   Latest:  ‘8-K’ on / for 2/6/24   ·   8 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/04/21  Amgen Inc.                        8-K:1,7,9   3/04/21   13:786K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     49K 
 2: EX-2.1      Plan of Acquisition, Reorganization, Arrangement,   HTML    322K 
                Liquidation or Succession                                        
 3: EX-99.1     Miscellaneous Exhibit                               HTML     31K 
 9: R1          Document and Entity Information                     HTML     53K 
11: XML         IDEA XML File -- Filing Summary                      XML     13K 
 8: XML         XBRL Instance -- d151856d8k_htm                      XML     21K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 5: EX-101.DEF  XBRL Definitions -- amgn-20210304_def                XML     42K 
 6: EX-101.LAB  XBRL Labels -- amgn-20210304_lab                     XML     68K 
 7: EX-101.PRE  XBRL Presentations -- amgn-20210304_pre              XML     43K 
 4: EX-101.SCH  XBRL Schema -- amgn-20210304                         XSD     15K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    22K 
13: ZIP         XBRL Zipped Folder -- 0001193125-21-068571-xbrl      Zip    102K 


‘XML’   —   XBRL Instance — d151856d8k_htm


This Document is an XBRL XML File.


                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:amgn="http://www.amgen.com/20210304" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink">
<link:schemaRef xlink:href="amgn-20210304.xsd" xlink:type="simple"/>
<context id="duration_2021-03-04_to_2021-03-04">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000318154 </identifier>
</entity>
<period>
<startDate> 2021-03-04 </startDate>
<endDate> 2021-03-04 </endDate>
</period>
</context>
<context id="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000318154 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-04 </startDate>
<endDate> 2021-03-04 </endDate>
</period>
</context>
<context id="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000318154 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> amgn:A1.250SeniorNotesDue2022Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-04 </startDate>
<endDate> 2021-03-04 </endDate>
</period>
</context>
<context id="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000318154 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> amgn:A2.00SeniorNotesDue2026Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-04 </startDate>
<endDate> 2021-03-04 </endDate>
</period>
</context>
<dei:EntityCentralIndexKey contextRef="duration_2021-03-04_to_2021-03-04" id="Hidden_dei_EntityCentralIndexKey_duration_2021-03-04_to_2021-03-04"> 0000318154 </dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="duration_2021-03-04_to_2021-03-04" id="Hidden_dei_AmendmentFlag_duration_2021-03-04_to_2021-03-04"> false </dei:AmendmentFlag>
<dei:DocumentType contextRef="duration_2021-03-04_to_2021-03-04"> 8-K </dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="duration_2021-03-04_to_2021-03-04"> 2021-03-04 </dei:DocumentPeriodEndDate>
<dei:EntityRegistrantName contextRef="duration_2021-03-04_to_2021-03-04"> Amgen Inc. </dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode contextRef="duration_2021-03-04_to_2021-03-04"> DE </dei:EntityIncorporationStateCountryCode>
<dei:EntityFileNumber contextRef="duration_2021-03-04_to_2021-03-04"> 001-37702 </dei:EntityFileNumber>
<dei:EntityTaxIdentificationNumber contextRef="duration_2021-03-04_to_2021-03-04"> 95-3540776 </dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="duration_2021-03-04_to_2021-03-04"> One Amgen Center Drive </dei:EntityAddressAddressLine1>
<dei:EntityAddressCityOrTown contextRef="duration_2021-03-04_to_2021-03-04"> Thousand Oaks </dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="duration_2021-03-04_to_2021-03-04"> CA </dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="duration_2021-03-04_to_2021-03-04"> 91320-1799 </dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="duration_2021-03-04_to_2021-03-04"> 805 </dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="duration_2021-03-04_to_2021-03-04"> 447-1000 </dei:LocalPhoneNumber>
<dei:WrittenCommunications contextRef="duration_2021-03-04_to_2021-03-04"> false </dei:WrittenCommunications>
<dei:SolicitingMaterial contextRef="duration_2021-03-04_to_2021-03-04"> false </dei:SolicitingMaterial>
<dei:PreCommencementTenderOffer contextRef="duration_2021-03-04_to_2021-03-04"> true </dei:PreCommencementTenderOffer>
<dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-03-04_to_2021-03-04"> false </dei:PreCommencementIssuerTenderOffer>
<dei:Security12bTitle contextRef="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> Common Stock $0.0001 par value </dei:Security12bTitle>
<dei:TradingSymbol contextRef="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> AMGN </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> NASDAQ </dei:SecurityExchangeName>
<dei:Security12bTitle contextRef="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member"> 1.250% Senior Notes Due 2022 </dei:Security12bTitle>
<dei:TradingSymbol contextRef="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member"> AMGN22 </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member"> NASDAQ </dei:SecurityExchangeName>
<dei:Security12bTitle contextRef="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member"> 2.000% Senior Notes Due 2026 </dei:Security12bTitle>
<dei:TradingSymbol contextRef="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member"> AMGN26 </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="duration_2021-03-04_to_2021-03-04_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member"> NASDAQ </dei:SecurityExchangeName>
<dei:EntityEmergingGrowthCompany contextRef="duration_2021-03-04_to_2021-03-04"> false </dei:EntityEmergingGrowthCompany>
</xbrl>


8 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/03/21  Amgen Inc.                        10-Q        9/30/21   80:11M
 8/06/21  Amgen Inc.                        424B2                  1:596K                                   Donnelley … Solutions/FA
 8/05/21  Amgen Inc.                        424B3                  1:577K                                   Donnelley … Solutions/FA
 8/04/21  Amgen Inc.                        10-Q        6/30/21   79:11M
 4/28/21  Amgen Inc.                        10-Q        3/31/21   74:8.3M
 4/16/21  Amgen Inc.                        8-K:2,7,9   4/16/21   12:221K                                   Donnelley … Solutions/FA
 4/15/21  Amgen Inc.                        424B3                  1:317K                                   Donnelley … Solutions/FA
 3/18/21  Amgen Inc.                        SC TO-T               11:1.1M Five Prime Therapeutics, Inc.     Donnelley … Solutions/FA
Top
Filing Submission 0001193125-21-068571   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 2:38:38.1pm ET